 | • レポートコード：D005-16223 • 出版社/出版日：GlobalInfoResearch / 2020年5月26日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、135ページ • 納品方法：Eメール • 産業分類：医療・製薬 |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥783,000 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、泌尿器がん治療薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。泌尿器がん治療薬の種類別市場規模（錠剤、注射剤）、用途別市場規模（前立腺がん、膀胱がん、腎臓がん、精巣がん、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、メーカー別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・メーカー情報（販売量、市場シェア、製品概要、SWOT分析）：Novartis、Celgene Corporation、AstraZeneca、Pfizer、Abbott Laboratories、Johnson & Johnson、Ferring Pharmaceuticals、Bristol-Myers Squibb、Astellas、Dendreon Corporation、Sanofi S.A、GlaxoSmithKline、Tolmar Inc、Roche Healthcare、Indevus Pharmaceuticals Inc、Ipsen ・地域別グローバル市場分析 2015年-2020年 ・泌尿器がん治療薬の北米市場（アメリカ、カナダ、メキシコ） ・泌尿器がん治療薬のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・泌尿器がん治療薬のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・泌尿器がん治療薬の南米市場（ブラジル、アルゼンチン） ・泌尿器がん治療薬の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：錠剤、注射剤 ・用途別分析：前立腺がん、膀胱がん、腎臓がん、精巣がん、その他 ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論 |
Market Overview
The global Urological Cancer Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Urological Cancer Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Urological Cancer Drugs market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Urological Cancer Drugs market has been segmented into
Tablets
Injection
By Application, Urological Cancer Drugs has been segmented into:
Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular Cancer
Other
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Urological Cancer Drugs market presented in the report. This section sheds light on the sales growth of different regional and country-level Urological Cancer Drugs markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Urological Cancer Drugs market.
The report offers in-depth assessment of the growth and other aspects of the Urological Cancer Drugs market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and Urological Cancer Drugs Market Share Analysis
Urological Cancer Drugs competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Urological Cancer Drugs sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Urological Cancer Drugs sales, revenue and market share for each player covered in this report.
The major players covered in Urological Cancer Drugs are:
Novartis
Celgene Corporation
AstraZeneca
Pfizer
Abbott Laboratories
Johnson & Johnson
Ferring Pharmaceuticals
Bristol-Myers Squibb
Astellas
Dendreon Corporation
Sanofi S.A
GlaxoSmithKline
Tolmar Inc
Roche Healthcare
Indevus Pharmaceuticals Inc
Ipsen
Among other players domestic and global, Urological Cancer Drugs market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Urological Cancer Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Urological Cancer Drugs, with price, sales, revenue and global market share of Urological Cancer Drugs in 2018 and 2019.
Chapter 3, the Urological Cancer Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Urological Cancer Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Urological Cancer Drugs market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Urological Cancer Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
1.1 Urological Cancer Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Urological Cancer Drugs Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Tablets
1.2.3 Injection
1.3 Market Analysis by Application
1.3.1 Overview: Global Urological Cancer Drugs Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Prostate Cancer
1.3.3 Bladder Cancer
1.3.4 Kidney Cancer
1.3.5 Testicular Cancer
1.3.6 Other
1.4 Overview of Global Urological Cancer Drugs Market
1.4.1 Global Urological Cancer Drugs Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Novartis
2.1.1 Novartis Details
2.1.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Novartis SWOT Analysis
2.1.4 Novartis Product and Services
2.1.5 Novartis Urological Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Celgene Corporation
2.2.1 Celgene Corporation Details
2.2.2 Celgene Corporation Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Celgene Corporation SWOT Analysis
2.2.4 Celgene Corporation Product and Services
2.2.5 Celgene Corporation Urological Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 AstraZeneca
2.3.1 AstraZeneca Details
2.3.2 AstraZeneca Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 AstraZeneca SWOT Analysis
2.3.4 AstraZeneca Product and Services
2.3.5 AstraZeneca Urological Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 Pfizer
2.4.1 Pfizer Details
2.4.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Pfizer SWOT Analysis
2.4.4 Pfizer Product and Services
2.4.5 Pfizer Urological Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 Abbott Laboratories
2.5.1 Abbott Laboratories Details
2.5.2 Abbott Laboratories Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Abbott Laboratories SWOT Analysis
2.5.4 Abbott Laboratories Product and Services
2.5.5 Abbott Laboratories Urological Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 Johnson & Johnson
2.6.1 Johnson & Johnson Details
2.6.2 Johnson & Johnson Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Johnson & Johnson SWOT Analysis
2.6.4 Johnson & Johnson Product and Services
2.6.5 Johnson & Johnson Urological Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 Ferring Pharmaceuticals
2.7.1 Ferring Pharmaceuticals Details
2.7.2 Ferring Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Ferring Pharmaceuticals SWOT Analysis
2.7.4 Ferring Pharmaceuticals Product and Services
2.7.5 Ferring Pharmaceuticals Urological Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.8 Bristol-Myers Squibb
2.8.1 Bristol-Myers Squibb Details
2.8.2 Bristol-Myers Squibb Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Bristol-Myers Squibb SWOT Analysis
2.8.4 Bristol-Myers Squibb Product and Services
2.8.5 Bristol-Myers Squibb Urological Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.9 Astellas
2.9.1 Astellas Details
2.9.2 Astellas Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Astellas SWOT Analysis
2.9.4 Astellas Product and Services
2.9.5 Astellas Urological Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.10 Dendreon Corporation
2.10.1 Dendreon Corporation Details
2.10.2 Dendreon Corporation Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Dendreon Corporation SWOT Analysis
2.10.4 Dendreon Corporation Product and Services
2.10.5 Dendreon Corporation Urological Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.11 Sanofi S.A
2.11.1 Sanofi S.A Details
2.11.2 Sanofi S.A Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Sanofi S.A SWOT Analysis
2.11.4 Sanofi S.A Product and Services
2.11.5 Sanofi S.A Urological Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.12 GlaxoSmithKline
2.12.1 GlaxoSmithKline Details
2.12.2 GlaxoSmithKline Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 GlaxoSmithKline SWOT Analysis
2.12.4 GlaxoSmithKline Product and Services
2.12.5 GlaxoSmithKline Urological Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.13 Tolmar Inc
2.13.1 Tolmar Inc Details
2.13.2 Tolmar Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 Tolmar Inc SWOT Analysis
2.13.4 Tolmar Inc Product and Services
2.13.5 Tolmar Inc Urological Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.14 Roche Healthcare
2.14.1 Roche Healthcare Details
2.14.2 Roche Healthcare Major Business and Total Revenue (Financial Highlights) Analysis
2.14.3 Roche Healthcare SWOT Analysis
2.14.4 Roche Healthcare Product and Services
2.14.5 Roche Healthcare Urological Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.15 Indevus Pharmaceuticals Inc
2.15.1 Indevus Pharmaceuticals Inc Details
2.15.2 Indevus Pharmaceuticals Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.15.3 Indevus Pharmaceuticals Inc SWOT Analysis
2.15.4 Indevus Pharmaceuticals Inc Product and Services
2.15.5 Indevus Pharmaceuticals Inc Urological Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.16 Ipsen
2.16.1 Ipsen Details
2.16.2 Ipsen Major Business and Total Revenue (Financial Highlights) Analysis
2.16.3 Ipsen SWOT Analysis
2.16.4 Ipsen Product and Services
2.16.5 Ipsen Urological Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Urological Cancer Drugs Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Urological Cancer Drugs Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Urological Cancer Drugs Manufacturer Market Share in 2019
3.3.2 Top 6 Urological Cancer Drugs Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Urological Cancer Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Urological Cancer Drugs Sales and Market Share by Regions (2015-2020)
4.1.2 Global Urological Cancer Drugs Revenue and Market Share by Regions (2015-2020)
4.2 North America Urological Cancer Drugs Sales and Growth Rate (2015-2020)
4.3 Europe Urological Cancer Drugs Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Urological Cancer Drugs Sales and Growth Rate (2015-2020)
4.5 South America Urological Cancer Drugs Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Urological Cancer Drugs Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Urological Cancer Drugs Sales, Revenue and Market Share by Country
5.1.1 North America Urological Cancer Drugs Sales and Market Share by Country (2015-2020)
5.1.2 North America Urological Cancer Drugs Revenue and Market Share by Country (2015-2020)
5.2 United States Urological Cancer Drugs Sales and Growth Rate (2015-2020)
5.3 Canada Urological Cancer Drugs Sales and Growth Rate (2015-2020)
5.4 Mexico Urological Cancer Drugs Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Urological Cancer Drugs Sales, Revenue and Market Share by Country
6.1.1 Europe Urological Cancer Drugs Sales and Market Share by Country (2015-2020)
6.1.2 Europe Urological Cancer Drugs Revenue and Market Share by Country (2015-2020)
6.2 Germany Urological Cancer Drugs Sales and Growth Rate (2015-2020)
6.3 UK Urological Cancer Drugs Sales and Growth Rate (2015-2020)
6.4 France Urological Cancer Drugs Sales and Growth Rate (2015-2020)
6.5 Russia Urological Cancer Drugs Sales and Growth Rate (2015-2020)
6.6 Italy Urological Cancer Drugs Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Urological Cancer Drugs Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Urological Cancer Drugs Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Urological Cancer Drugs Revenue and Market Share by Regions (2015-2020)
7.2 China Urological Cancer Drugs Sales and Growth Rate (2015-2020)
7.3 Japan Urological Cancer Drugs Sales and Growth Rate (2015-2020)
7.4 Korea Urological Cancer Drugs Sales and Growth Rate (2015-2020)
7.5 India Urological Cancer Drugs Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Urological Cancer Drugs Sales and Growth Rate (2015-2020)
7.7 Australia Urological Cancer Drugs Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Urological Cancer Drugs Sales, Revenue and Market Share by Country
8.1.1 South America Urological Cancer Drugs Sales and Market Share by Country (2015-2020)
8.1.2 South America Urological Cancer Drugs Revenue and Market Share by Country (2015-2020)
8.2 Brazil Urological Cancer Drugs Sales and Growth Rate (2015-2020)
8.3 Argentina Urological Cancer Drugs Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Urological Cancer Drugs Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Urological Cancer Drugs Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Urological Cancer Drugs Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Urological Cancer Drugs Sales and Growth Rate (2015-2020)
9.3 Turkey Urological Cancer Drugs Sales and Growth Rate (2015-2020)
9.4 Egypt Urological Cancer Drugs Sales and Growth Rate (2015-2020)
9.5 South Africa Urological Cancer Drugs Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Urological Cancer Drugs Sales and Market Share by Type (2015-2020)
10.2 Global Urological Cancer Drugs Revenue and Market Share by Type (2015-2020)
10.3 Global Urological Cancer Drugs Price by Type (2015-2020)
11 Global Urological Cancer Drugs Market Segment by Application
11.1 Global Urological Cancer Drugs Sales Market Share by Application (2015-2020)
11.2 Global Urological Cancer Drugs Revenue Market Share by Application (2015-2020)
11.3 Global Urological Cancer Drugs Price by Application (2015-2020)
12 Market Forecast
12.1 Global Urological Cancer Drugs Sales, Revenue and Growth Rate (2021-2025)
12.2 Urological Cancer Drugs Market Forecast by Regions (2021-2025)
12.2.1 North America Urological Cancer Drugs Market Forecast (2021-2025)
12.2.2 Europe Urological Cancer Drugs Market Forecast (2021-2025)
12.2.3 Asia-Pacific Urological Cancer Drugs Market Forecast (2021-2025)
12.2.4 South America Urological Cancer Drugs Market Forecast (2021-2025)
12.2.5 Middle East & Africa Urological Cancer Drugs Market Forecast (2021-2025)
12.3 Urological Cancer Drugs Market Forecast by Type (2021-2025)
12.3.1 Global Urological Cancer Drugs Sales Forecast by Type (2021-2025)
12.3.2 Global Urological Cancer Drugs Market Share Forecast by Type (2021-2025)
12.4 Urological Cancer Drugs Market Forecast by Application (2021-2025)
12.4.1 Global Urological Cancer Drugs Sales Forecast by Application (2021-2025)
12.4.2 Global Urological Cancer Drugs Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global Urological Cancer Drugs Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Urological Cancer Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Urological Cancer Drugs Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Market Opportunities in Next Few Years
Table 5. Market Risks Analysis
Table 6. Market Drivers
Table 7. Novartis Basic Information, Manufacturing Base and Competitors
Table 8. Novartis Urological Cancer Drugs Major Business
Table 9. Novartis Urological Cancer Drugs Total Revenue (USD Million) (2018-2019)
Table 10. Novartis SWOT Analysis
Table 11. Novartis Urological Cancer Drugs Product and Services
Table 12. Novartis Urological Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 13. Celgene Corporation Basic Information, Manufacturing Base and Competitors
Table 14. Celgene Corporation Urological Cancer Drugs Major Business
Table 15. Celgene Corporation Urological Cancer Drugs Total Revenue (USD Million) (2018-2019)
Table 16. Celgene Corporation SWOT Analysis
Table 17. Celgene Corporation Urological Cancer Drugs Product and Services
Table 18. Celgene Corporation Urological Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 19. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 20. AstraZeneca Urological Cancer Drugs Major Business
Table 21. AstraZeneca Urological Cancer Drugs Total Revenue (USD Million) (2018-2019)
Table 22. AstraZeneca SWOT Analysis
Table 23. AstraZeneca Urological Cancer Drugs Product and Services
Table 24. AstraZeneca Urological Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 25. Pfizer Basic Information, Manufacturing Base and Competitors
Table 26. Pfizer Urological Cancer Drugs Major Business
Table 27. Pfizer Urological Cancer Drugs Total Revenue (USD Million) (2018-2019)
Table 28. Pfizer SWOT Analysis
Table 29. Pfizer Urological Cancer Drugs Product and Services
Table 30. Pfizer Urological Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 31. Abbott Laboratories Basic Information, Manufacturing Base and Competitors
Table 32. Abbott Laboratories Urological Cancer Drugs Major Business
Table 33. Abbott Laboratories Urological Cancer Drugs Total Revenue (USD Million) (2018-2019)
Table 34. Abbott Laboratories SWOT Analysis
Table 35. Abbott Laboratories Urological Cancer Drugs Product and Services
Table 36. Abbott Laboratories Urological Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 37. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 38. Johnson & Johnson Urological Cancer Drugs Major Business
Table 39. Johnson & Johnson Urological Cancer Drugs Total Revenue (USD Million) (2018-2019)
Table 40. Johnson & Johnson SWOT Analysis
Table 41. Johnson & Johnson Urological Cancer Drugs Product and Services
Table 42. Johnson & Johnson Urological Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 43. Ferring Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 44. Ferring Pharmaceuticals Urological Cancer Drugs Major Business
Table 45. Ferring Pharmaceuticals Urological Cancer Drugs Total Revenue (USD Million) (2018-2019)
Table 46. Ferring Pharmaceuticals SWOT Analysis
Table 47. Ferring Pharmaceuticals Urological Cancer Drugs Product and Services
Table 48. Ferring Pharmaceuticals Urological Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 49. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 50. Bristol-Myers Squibb Urological Cancer Drugs Major Business
Table 51. Bristol-Myers Squibb Urological Cancer Drugs Total Revenue (USD Million) (2018-2019)
Table 52. Bristol-Myers Squibb SWOT Analysis
Table 53. Bristol-Myers Squibb Urological Cancer Drugs Product and Services
Table 54. Bristol-Myers Squibb Urological Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 55. Astellas Basic Information, Manufacturing Base and Competitors
Table 56. Astellas Urological Cancer Drugs Major Business
Table 57. Astellas Urological Cancer Drugs Total Revenue (USD Million) (2018-2019)
Table 58. Astellas SWOT Analysis
Table 59. Astellas Urological Cancer Drugs Product and Services
Table 60. Astellas Urological Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 61. Dendreon Corporation Basic Information, Manufacturing Base and Competitors
Table 62. Dendreon Corporation Urological Cancer Drugs Major Business
Table 63. Dendreon Corporation Urological Cancer Drugs Total Revenue (USD Million) (2018-2019)
Table 64. Dendreon Corporation SWOT Analysis
Table 65. Dendreon Corporation Urological Cancer Drugs Product and Services
Table 66. Dendreon Corporation Urological Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 67. Sanofi S.A Basic Information, Manufacturing Base and Competitors
Table 68. Sanofi S.A Urological Cancer Drugs Major Business
Table 69. Sanofi S.A Urological Cancer Drugs Total Revenue (USD Million) (2018-2019)
Table 70. Sanofi S.A SWOT Analysis
Table 71. Sanofi S.A Urological Cancer Drugs Product and Services
Table 72. Sanofi S.A Urological Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 73. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 74. GlaxoSmithKline Urological Cancer Drugs Major Business
Table 75. GlaxoSmithKline Urological Cancer Drugs Total Revenue (USD Million) (2018-2019)
Table 76. GlaxoSmithKline SWOT Analysis
Table 77. GlaxoSmithKline Urological Cancer Drugs Product and Services
Table 78. GlaxoSmithKline Urological Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 79. Tolmar Inc Basic Information, Manufacturing Base and Competitors
Table 80. Tolmar Inc Urological Cancer Drugs Major Business
Table 81. Tolmar Inc Urological Cancer Drugs Total Revenue (USD Million) (2018-2019)
Table 82. Tolmar Inc SWOT Analysis
Table 83. Tolmar Inc Urological Cancer Drugs Product and Services
Table 84. Tolmar Inc Urological Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 85. Roche Healthcare Basic Information, Manufacturing Base and Competitors
Table 86. Roche Healthcare Urological Cancer Drugs Major Business
Table 87. Roche Healthcare Urological Cancer Drugs Total Revenue (USD Million) (2018-2019)
Table 88. Roche Healthcare SWOT Analysis
Table 89. Roche Healthcare Urological Cancer Drugs Product and Services
Table 90. Roche Healthcare Urological Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 91. Indevus Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table 92. Indevus Pharmaceuticals Inc Urological Cancer Drugs Major Business
Table 93. Indevus Pharmaceuticals Inc Urological Cancer Drugs Total Revenue (USD Million) (2018-2019)
Table 94. Indevus Pharmaceuticals Inc SWOT Analysis
Table 95. Indevus Pharmaceuticals Inc Urological Cancer Drugs Product and Services
Table 96. Indevus Pharmaceuticals Inc Urological Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 97. Ipsen Basic Information, Manufacturing Base and Competitors
Table 98. Ipsen Urological Cancer Drugs Major Business
Table 99. Ipsen Urological Cancer Drugs Total Revenue (USD Million) (2018-2019)
Table 100. Ipsen SWOT Analysis
Table 101. Ipsen Urological Cancer Drugs Product and Services
Table 102. Ipsen Urological Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 103. Global Urological Cancer Drugs Sales by Manufacturer (2018-2019) (K Pcs)
Table 104. Global Urological Cancer Drugs Revenue by Manufacturer (2018-2019) (USD Million)
Table 105. Global Urological Cancer Drugs Sales by Regions (2015-2020) (K Pcs)
Table 106. Global Urological Cancer Drugs Sales Market Share by Regions (2015-2020)
Table 107. Global Urological Cancer Drugs Revenue by Regions (2015-2020) (USD Million)
Table 108. North America Urological Cancer Drugs Sales by Countries (2015-2020) (K Pcs)
Table 109. North America Urological Cancer Drugs Sales Market Share by Countries (2015-2020)
Table 110. North America Urological Cancer Drugs Revenue by Countries (2015-2020) (USD Million)
Table 111. North America Urological Cancer Drugs Revenue Market Share by Countries (2015-2020)
Table 112. Europe Urological Cancer Drugs Sales by Countries (2015-2020) (K Pcs)
Table 113. Europe Urological Cancer Drugs Sales Market Share by Countries (2015-2020)
Table 114. Europe Urological Cancer Drugs Revenue by Countries (2015-2020) (USD Million)
Table 115. Asia-Pacific Urological Cancer Drugs Sales by Regions (2015-2020) (K Pcs)
Table 116. Asia-Pacific Urological Cancer Drugs Sales Market Share by Regions (2015-2020)
Table 117. Asia-Pacific Urological Cancer Drugs Revenue by Regions (2015-2020) (USD Million)
Table 118. South America Urological Cancer Drugs Sales by Countries (2015-2020) (K Pcs)
Table 119. South America Urological Cancer Drugs Sales Market Share by Countries (2015-2020)
Table 120. South America Urological Cancer Drugs Revenue by Countries (2015-2020) (USD Million)
Table 121. South America Urological Cancer Drugs Revenue Market Share by Countries (2015-2020)
Table 122. Middle East & Africa Urological Cancer Drugs Sales by Countries (2015-2020) (K Pcs)
Table 123. Middle East & Africa Urological Cancer Drugs Sales Market Share by Countries (2015-2020)
Table 124. Middle East & Africa Urological Cancer Drugs Revenue by Countries (2015-2020) (USD Million)
Table 125. Middle East & Africa Urological Cancer Drugs Revenue Market Share by Countries (2015-2020)
Table 126. Global Urological Cancer Drugs Sales by Type (2015-2020) (K Pcs)
Table 127. Global Urological Cancer Drugs Sales Share by Type (2015-2020)
Table 128. Global Urological Cancer Drugs Revenue by Type (2015-2020) (USD Million)
Table 129. Global Urological Cancer Drugs Revenue Share by Type (2015-2020)
Table 130. Global Urological Cancer Drugs Sales by Application (2015-2020) (K Pcs)
Table 131. Global Urological Cancer Drugs Sales Share by Application (2015-2020)
Table 132. Global Urological Cancer Drugs Sales Forecast by Regions (2021-2025) (K Pcs)
Table 133. Global Urological Cancer Drugs Market Share Forecast by Regions (2021-2025)
Table 134. Global Urological Cancer Drugs Sales Forecast by Type (2021-2025) (K Pcs)
Table 135. Global Urological Cancer Drugs Market Share Forecast by Type (2021-2025)
Table 136. Global Urological Cancer Drugs Sales Forecast by Application (2021-2025)
Table 137. Global Urological Cancer Drugs Market Share Forecast by Application (2021-2025)
Table 138. Direct Channel Pros & Cons
Table 139. Indirect Channel Pros & Cons
Table 140. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Urological Cancer Drugs Picture
Figure 2. Global Sales Market Share of Urological Cancer Drugs by Type in 2019
Figure 3. Tablets Picture
Figure 4. Injection Picture
Figure 5. Urological Cancer Drugs Sales Market Share by Application in 2018
Figure 6. Prostate Cancer Picture
Figure 7. Bladder Cancer Picture
Figure 8. Kidney Cancer Picture
Figure 9. Testicular Cancer Picture
Figure 10. Other Picture
Figure 11. Global Urological Cancer Drugs Market Status and Outlook (2015-2025) (USD Million)
Figure 12. United States Urological Cancer Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 13. Canada Urological Cancer Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 14. Mexico Urological Cancer Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 15. Germany Urological Cancer Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 16. France Urological Cancer Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 17. UK Urological Cancer Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 18. Russia Urological Cancer Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 19. Italy Urological Cancer Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 20. China Urological Cancer Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 21. Japan Urological Cancer Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 22. Korea Urological Cancer Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 23. India Urological Cancer Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 24. Southeast Asia Urological Cancer Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 25. Australia Urological Cancer Drugs Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 26. Brazil Urological Cancer Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 27. Egypt Urological Cancer Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 28. Saudi Arabia Urological Cancer Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 29. South Africa Urological Cancer Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 30. Turkey Urological Cancer Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 31. Global Urological Cancer Drugs Sales Market Share by Manufacturer in 2019
Figure 32. Global Urological Cancer Drugs Revenue Market Share by Manufacturer in 2019
Figure 33. Top 3 Urological Cancer Drugs Manufacturer (Revenue) Market Share in 2019
Figure 34. Top 6 Urological Cancer Drugs Manufacturer (Revenue) Market Share in 2019
Figure 35. Key Manufacturer Market Share Trend
Figure 36. Global Urological Cancer Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 37. Global Urological Cancer Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 38. Global Urological Cancer Drugs Revenue Market Share by Regions (2015-2020)
Figure 39. Global Urological Cancer Drugs Revenue Market Share by Regions in 2018
Figure 40. North America Urological Cancer Drugs Sales and Growth Rate (2015-2020)
Figure 41. Europe Urological Cancer Drugs Sales and Growth Rate (2015-2020)
Figure 42. Asia-Pacific Urological Cancer Drugs Sales and Growth Rate (2015-2020)
Figure 43. South America Urological Cancer Drugs Sales and Growth Rate (2015-2020)
Figure 44. Middle East & Africa Urological Cancer Drugs Sales and Growth Rate (2015-2020)
Figure 45. North America Urological Cancer Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 46. North America Urological Cancer Drugs Sales Market Share by Countries (2015-2020)
Figure 47. North America Urological Cancer Drugs Sales Market Share by Countries in 2018
Figure 48. North America Urological Cancer Drugs Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 49. North America Urological Cancer Drugs Revenue Market Share by Countries in 2018
Figure 50. United States Urological Cancer Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 51. Canada Urological Cancer Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 52. Mexico Urological Cancer Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 53. Europe Urological Cancer Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 54. Europe Urological Cancer Drugs Revenue Market Share by Countries (2015-2020)
Figure 55. Europe Urological Cancer Drugs Revenue Market Share by Countries in 2019
Figure 56. Germany Urological Cancer Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 57. UK Urological Cancer Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 58. France Urological Cancer Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 59. Russia Urological Cancer Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 60. Italy Urological Cancer Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 61. Asia-Pacific Urological Cancer Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 62. Asia-Pacific Urological Cancer Drugs Sales Market Share by Regions 2019
Figure 63. Asia-Pacific Urological Cancer Drugs Revenue Market Share by Regions 2019
Figure 64. China Urological Cancer Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 65. Japan Urological Cancer Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 66. Korea Urological Cancer Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 67. India Urological Cancer Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 68. Southeast Asia Urological Cancer Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 69. South America Urological Cancer Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 70. South America Urological Cancer Drugs Sales Market Share by Countries in 2019
Figure 71. South America Urological Cancer Drugs Revenue Market Share by Countries in 2019
Figure 72. Brazil Urological Cancer Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 73. Argentina Urological Cancer Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 74. Middle East and Africa Urological Cancer Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 75. Middle East and Africa Urological Cancer Drugs Sales Market Share by Countries in 2019
Figure 76. Middle East and Africa Urological Cancer Drugs Revenue Market Share by Countries (2015-2020)
Figure 77. Middle East and Africa Urological Cancer Drugs Revenue Market Share by Countries in 2019
Figure 78. Saudi Arabia Urological Cancer Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 79. Egypt Urological Cancer Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 80. Turkey Urological Cancer Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 81. South Africa Urological Cancer Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 82. Global Urological Cancer Drugs Sales and Growth Rate (2021-2025) (K Pcs)
Figure 83. Global Urological Cancer Drugs Revenue and Growth Rate (2021-2025) (USD Million)
Figure 84. North America Sales Urological Cancer Drugs Market Forecast (2021-2025) (K Pcs)
Figure 85. Europe Sales Urological Cancer Drugs Market Forecast (2021-2025) (K Pcs)
Figure 86. Asia-Pacific Sales Urological Cancer Drugs Market Forecast (2021-2025) (K Pcs)
Figure 87. South America Sales Urological Cancer Drugs Market Forecast (2021-2025) (K Pcs)
Figure 88. Middle East & Africa Sales Urological Cancer Drugs Market Forecast (2021-2025) (K Pcs)
Figure 89. Sales Channel: Direct Channel vs Indirect Channel
尿路上皮がん治療薬の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Urothelial Cancer Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 12.4% in the forecast period of 2020 to 2025 and will expected to reach USD 1565.9 million by 2025, from USD 980.1 million in 2019. The Urothelial C…- 卵巣がん治療薬の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Ovarian Cancer Treatment Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Ovarian Cancer…
- 子宮頸がん治療薬の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Cervical Cancer Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 2.2% in the forecast period of 2020 to 2025 and will expected to reach USD 14770 million by 2025, from USD 13550 million in 2019. The Cervical Cancer …
- 頭頸部がん治療薬/治療の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Head and Neck Cancer Drugs/Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 4.0% in the forecast period of 2020 to 2025 and will expected to reach USD 1466.9 million by 2025, from USD 1255.8 million in 2019. …
- 泌尿生殖器薬の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Genitourinary Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Genitourinary Drugs marke…